The Present and Future of Colorectal Cancer Screening

Overview

Journal Gastroenterol Hepatol (N Y)

Specialty Gastroenterology

Date 2023 Mar 3

PMID 36866031

Authors

Samantha S Chung

Sara I Ali

Brooks D Cash

Affiliations

Soon will be listed here.

Abstract

There have been multiple recent updates for recommendations pertaining to colorectal cancer (CRC) screening. Among the most notable is the recommendation from several guideline-issuing bodies to initiate CRC screening examinations at 45 years of age for individuals at average risk for CRC. Current CRC screening methods include stool-based tests and colon visualization examinations. Currently recommended stool-based tests include fecal immunochemical testing, high-sensitivity guaiac-based fecal occult blood testing, and multitarget stool DNA testing. Visualization examinations include colonoscopy, computed tomography colonography, colon capsule endoscopy, and flexible sigmoidoscopy. Although these screening tests have shown encouraging results for CRC detection, there are important differences between these testing modalities for precursor lesion detection and management. In addition, emerging CRC screening methods are being developed and evaluated. However, additional large, multicenter clinical trials in diverse populations are needed to validate the diagnostic accuracy and generalizability of these new tests. This article reviews the recently updated CRC screening recommendations and current and emerging testing options.

Citing Articles

The role of fungi in the diagnosis of colorectal cancer.

Li X, Luo M, Wang Z, Wang Q, Xu B Mycology. 2024; 15(1):17-29.

PMID: 38558845 PMC: 10977015. DOI: 10.1080/21501203.2023.2249492.

Role of microRNA in colorectal carcinoma (CRC): a narrative review.

Sado A, Batool W, Ahmed A, Zafar S, Patel S, Mohan A Ann Med Surg (Lond). 2024; 86(1):308-318.

PMID: 38222721 PMC: 10783342. DOI: 10.1097/MS9.0000000000001494.

The effect of adjuvant chemotherapy on survival in node negative colorectal cancer with or without perineural invasion: a systematic review and meta-analysis.

Ying H, Shao J, Liao N, Xu X, Yu W, Hong W Front Surg. 2023; 10:1308757.

PMID: 38033531 PMC: 10687374. DOI: 10.3389/fsurg.2023.1308757.

Colorectal Cancer Diagnostic Methods: The Present and Future.

Gude S, Veeravalli R, Vejandla B, Gude S, Venigalla T, Chintagumpala V Cureus. 2023; 15(4):e37622.

PMID: 37197135 PMC: 10185295. DOI: 10.7759/cureus.37622.

References

Holme O, Loberg M, Kalager M, Bretthauer M, Hernan M, Aas E . Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014; 312(6):606-15. PMC: 4495882. DOI: 10.1001/jama.2014.8266. View

Park D, Ryu S, Kim Y, Lee S, Lee C, Eun C . Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010; 105(9):2017-25. DOI: 10.1038/ajg.2010.179. View

Jensen C, Corley D, Quinn V, Doubeni C, Zauber A, Lee J . Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016; 164(7):456-63. PMC: 4973858. DOI: 10.7326/M15-0983. View

Hong S, Kang S, Jang H, Wallace M . Recent Advance in Colon Capsule Endoscopy: What's New?. Clin Endosc. 2018; 51(4):334-343. PMC: 6078933. DOI: 10.5946/ce.2018.121. View

Parente F, Boemo C, Ardizzoia A, Costa M, Carzaniga P, Ilardo A . Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy. 2012; 45(1):27-34. DOI: 10.1055/s-0032-1325800. View

Scholefield J, Moss S, Mangham C, Whynes D, Hardcastle J . Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2011; 61(7):1036-40. DOI: 10.1136/gutjnl-2011-300774. View

Cooper G, Markowitz S, Chen Z, Tuck M, Willis J, Berger B . Performance of multitarget stool DNA testing in African American patients. Cancer. 2018; 124(19):3876-3880. PMC: 6226346. DOI: 10.1002/cncr.31660. View

Kapidzic A, Grobbee E, Hol L, van Roon A, van Vuuren A, Spijker W . Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol. 2014; 109(8):1257-64. DOI: 10.1038/ajg.2014.168. View

Zhou W, Tao J, Li J, Tao S . Volatile organic compounds analysis as a potential novel screening tool for colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(27):e20937. PMC: 7337537. DOI: 10.1097/MD.0000000000020937. View

10.

Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W . Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med. 2005; 352(20):2061-8. DOI: 10.1056/NEJMoa042990. View

11.

Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S . The role of SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019; 19(1):450. PMC: 6518628. DOI: 10.1186/s12885-019-5663-8. View

12.

Denters M, Deutekom M, Bossuyt P, Stroobants A, Fockens P, Dekker E . Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2011; 142(3):497-504. DOI: 10.1053/j.gastro.2011.11.024. View

13.

Patel S, Kilgore M . Cost Effectiveness of Colorectal Cancer Screening Strategies. Cancer Control. 2015; 22(2):248-58. DOI: 10.1177/107327481502200219. View

14.

Stegeman I, van Doorn S, Mundt M, Mallant-Hent R, Bongers E, Elferink M . Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol. 2015; 39(3):388-93. DOI: 10.1016/j.canep.2015.03.012. View

15.

Bosch L, Melotte V, Mongera S, Daenen K, Coupe V, van Turenhout S . Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Am J Gastroenterol. 2019; 114(12):1909-1918. PMC: 6903367. DOI: 10.14309/ajg.0000000000000445. View

16.

Kronborg O, Jorgensen O, Fenger C, Rasmussen M . Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004; 39(9):846-51. DOI: 10.1080/00365520410003182. View

17.

Lansdorp-Vogelaar I, Knudsen A, Brenner H . Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011; 33:88-100. PMC: 3132805. DOI: 10.1093/epirev/mxr004. View

18.

Wolf A, Fontham E, Church T, Flowers C, Guerra C, LaMonte S . Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018; 68(4):250-281. DOI: 10.3322/caac.21457. View

19.

Imperiale T, Gruber R, Stump T, Emmett T, Monahan P . Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis. Ann Intern Med. 2019; 170(5):319-329. DOI: 10.7326/M18-2390. View

20.

Chiu H, Chen S, Yen A, Chiu S, Fann J, Lee Y . Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015; 121(18):3221-9. PMC: 4676309. DOI: 10.1002/cncr.29462. View